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Cancer is nowadays recognised as a genetic and epigenetic disease. Much effort has been devoted in the last 30 years to the
elucidation of the ‘classical’ oncogenes and tumour-suppressor genes involved in malignant cell transformation. However, since the
acceptance that major disruption of DNA methylation, histone modification and chromatin compartments are a common hallmark of
human cancer, epigenetics has come to the fore in cancer research. One piece is still missing from the story: are the epigenetic genes
themselves driving forces on the road to tumorigenesis? We are in the early stages of finding the answer, and the data are beginning
to appear: knockout mice defective in DNA methyltransferases, methyl-CpG-binding proteins and histone methyltransferases
strongly affect the risk of cancer onset; somatic mutations, homozygous deletions and methylation-associated silencing of histone
acetyltransferases, histone methyltransferases and chromatin remodelling factors are being found in human tumours; and the first
cancer-prone families arising from germline mutations in epigenetic genes, such as hSNF5/INI1, have been described. Even more
importantly, all these ‘new’ oncogenes and tumour-suppressor genes provide novel molecular targets for designed therapies, and the
first DNA-demethylating agents and inhibitors of histone deacetylases are reaching the bedside of patients with haematological
malignancies.
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CANCER AS AN EPIGENETIC DISEASE
Great effort has been directed in recent years towards under-
standing the establishment and relevance of aberrant epigenetic
patterns in human tumours. For DNA methylation, it is known
that two apparently contrasting phenomena coexist in the cancer
cell: a profound loss of global 5-methylcytosine genomic content
with discrete areas of dense hypermethylation (Jones and Baylin,
2002; Feinberg and Tycko, 2004; Esteller, 2005a). Overall
hypomethylation takes place predominantly in DNA repetitive
and endoparasitic sequences and has been linked to the generation
of chromosomal instability (Feinberg and Tycko, 2004; Esteller,
2005a). On the other hand, hypermethylation occurs in the CpG
islands located in the promoters of certain tumour-suppressor
genes, such as p16
INK4a, BRCA1 or hMLH, leading to gene silencing
(Jones and Baylin, 2002; Esteller, 2005a).
Histones are another key player in epigenetics. Today they are
recognised as having a primary role in the control of gene
expression and chromatin structure and are partners closely
involved with the DNA methylation machinery (Fraga and Esteller,
2005). Our knowledge of the behaviour of histones in cancer cells
is slight compared with that of DNA methylation. We know that
certain histone modifications participate in tumour-suppressor
gene silencing, in conjunction with CpG island hypermethylation
(Fahrner et al, 2002; Ballestar et al, 2003) or in its absence, such
as the case of p21
WAF1. Most importantly, we have recently
demonstrated that human tumours undergo an overall loss of
monoacetylation of lysine 16 and trimethylation of lysine 20 in the
tail of histone H4. These two histone-modification losses can be
considered as almost universal epigenetic markers of malignant
transformation (Fraga et al, 2005), as has now been accepted for
global DNA hypomethylation and CpG island hypermethylation.
Certain histone acetylation and methylation marks may have
prognostic value (Seligson et al, 2005).
Finally, we should not forget that DNA methylation and histone
modifications are not isolated events, but occur in higher-order
chromatin structure. Nucleosomes, formed by DNA wrapping
around an octamer of histones, are the champions of that league.
Multi-subunit complexes, such as those constituted by the SWI/
SNF proteins, use the energy of ATP to mobilise nucleosomes and
allow the access of the transcriptional machinery (Gibbons, 2005);
or massive repressive complexes counteract SWI/SNF functions, as
does the polycomb group gene family (Valk-Lingbeek et al, 2004).
In the end, the impact on gene expression in cancer cells is massive
and the normal epigenetic programming of the healthy cell
becomes merely a faint memory.
Never the less, several pieces of the jigsaw are still missing. Are
there molecular alterations acting as ‘dark horses’ behind this
distorted epigenetic pattern? Could the epigenetic genes turn out to
be the next generation of oncogenes and tumour-suppressor
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www.bjcancer.comgenes? Could these genes be targeted with new drugs? Let us review
the data that is summarised in Figure 1 and Table 1.
GENES MEDIATING THE DISRUPTION OF DNA
METHYLATION
It has been known for a long time that there is more enzymatic
DNA methyltransferase activity overall in tumours than in
normal tissues (Esteller, 2005a,b). This finding has been
supported by the molecular characterisation of the genes
encoding several DNA methyltranferases (DNMT1, DNMT3a,
DNMT3b, DNMT3L and DNMT2), which has shown that the
number of mRNA transcripts of DNMT1 (the classical methylation
maintenance enzyme) and DNMT3b (the de novo methylation
enzyme) are greater in several solid and haematological malig-
nancies (Esteller, 2005a).
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Figure 1 Epigenetic proteins that contribute to human tumorigenesis. Silencing of a classical tumours suppressor gene involves the recruitment of a
transcriptional repressor machinery to the corresponding promoter CpG island, such as DNA methyltransferases (DNMT), methyl-CpG-binding proteins
(MBD), histone methyltransferases for lysine 9 of histone H3 (HMT K9 H3), histone deacetylases (HDAC) and polycomb (PcGs) complexes. In the other
side of the coin, the active expression of oncogenes in human cancer requires a potent transcriptional activation machinery, such as the one constituted by
the chromatin-remodelling factors SWI/SNF, histone acetyltransferases (HATs) and histone methyltransferases for lysine 4 of histone H3 (HMT K4 H3).
Table 1 A selected list of epigenetic genes disrupted in human cancer and additional potential candidates
Gene Function Alteration Tumour profile
DNMT1 DNA methyltransferase Overexpression Multiple types
DNMT3b DNA methyltransferase Overexpression Multiple types
MeCP2 Methyl-CpG-binding protein Overexpression, rare mutations Multiple types
MBD2 Methyl-CpG-binding protein Overexpression, rare mutations Multiple types
MBD1 Methyl-CpG-binding protein Overexpression, rare mutations Multiple types
MBD3 Methyl-CpG-binding protein Overexpression, rare mutations Multiple types
MBD4 Methyl-CpG-binding protein Inactivating mutations in MSI+ Colon, stomach, endometrium
p300 Histone acetyltransferase Mutations Colon, stomach, endometrium
CBP Histone acetyltransferase Mutations, homozygous deletions Colon, stomach, endometrium, lung
pCAF Histone acetyltransferase Rare mutations Colon
MOZ Histone acetyltransferase Translocations Haematological malignancies
MORF Histone acetyltransferase Translocations Haematological malignancies
MOF Histone acetyltransferase Unknown Unknown
HDAC1 Histone deacetylase Imbalanced expression Multiple types
HDAC2 Histone deacetylase Imbalanced expression Multiple types
SIRT1 Histone deacetylase Unknown Unknown
SUV39H1 Histone methyltransferase Unknown Unknown
Suv4-20h Histone methyltransferase Unknown Unknown
PR/SET7,8 Histone methyltransferase Unknown Unknown
RIZ1 Histone methyltransferase CpG island hypermethylation, mutation Multiple types
MLL1 Histone methyltransferase Translocation Haematological malignancies
BMI1 Polycomb-group protein Gene amplification, overexpression Haematological malignancies, brain
EZH2 Polycomb-group protein Gene amplification, overexpression Multiple types
EMSY Chromatin-remodelling factor Gene amplification, overexpression Breast
BRMS1 Chromatin-remodelling factor Loss of expression Breast
MTA1 Chromatin-remodelling factor Overexpression Breast, haematological malignancies
MTA3 Chromatin-remodelling factor Overexpression Breast, haematological malignancies
PASG/LSH SWI/SNF family protein Mutation Haematological malignancies
BRG1 SWI/SNF family protein Homozygous deletion, mutation Lung
HLTF SWI/SNF family protein CpG island hypermethylation Multiple types
SNF5 SWI/SNF family protein Somatic and germline mutations Rhabdoid tumours
MSI+¼microsatellite instable tumours.
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cell transformation. The genetic disruption of two DNMTs,
DNMT1 and DNMT3b, in a cancer cell line induces demethylation
of all known hypermethylated tumour-suppressor genes (Rhee
et al, 2002; Paz et al, 2003) and remarkably slow growth (Rhee
et al, 2002). Somatic DNMT mutations have not so far been
described in human tumours, although DNMT1 is located in
19p13.3, a region of common loss of heterozygosity in human
tumours. DNMT3b germline mutation are responsible for the
immunodeficiency centromeric instability-facial anomalies (ICF)
syndrome, the cancer risk of which is not known, while no DNMT1
germline mutation in any genetic syndrome has so far been
reported. Results obtained in mouse models again reflect the need
for well-adjusted DNMT function to maintain cellular homeostasis:
DNMT1 knockout mice are ‘protected’ against the development of
colorectal adenomas when crossed with APC-deficient mice (Laird
et al, 1995), but they are ‘prone’ to develop lymphomas in the
context of mice susceptible to this type of neoplasia (Eden et al,
2003). These latter results may be explained if lymphomas rely
predominantly on chromosomal instability dependent on genomic
DNA hypomethylation, while colon tumours rely more on the CpG
island methylation status of tumour-suppressor genes (Yamada
et al, 2005).
Something has to read the DNA methylation markers. The most
likely candidates are transcriptional repressors that have an
appetite for methylated CpGs. These are the methyl-CpG-binding
domain proteins (MBDs) (Esteller, 2005a). MBDs are important
‘translators’ between DNA methylation and histone modifier genes
that establish a transcriptionally inactive chromatin environment.
This family of proteins consists of five well-characterised members
(MeCP2, MBD1, MBD2, MBD3 and MBD4) (Esteller, 2005a). MBD
proteins are associated with hypermethylated CpG island promo-
ters of tumour-suppressor genes and their transcriptional silencing
(Esteller, 2005a), showing remarkable specificity in vitro (Fraga
et al, 2003) and in vivo (Ballestar et al, 2003; Klose et al, 2005).
Individual loss of MeCP2, MBD1, MBD2, for which single
knockout mice are viable, do not appear to affect tumour
formation significantly (Esteller, 2005a), which suggests that the
remaining MBDs may compensate for the function of the missing
one. However, deficiency of MBD2 suppresses intestinal tumor-
igenesis in an Mbd2-knockout mouse derived from a lineage with
an autosomal-dominantly inherited predisposition to multiple
intestinal neoplasia (Min) (Sansom et al, 2003). We can
hypothesise that the absence of MBD2 produces a ‘leak’ in the
CpG island hypermethylation silencing of tumour-suppressor
genes, thereby partially aborting aberrant cancer growth. This
may not be universal for all tumour types and in this regard
deficiency of MBD2 does not enhance lymphomagenesis in p53-
deficient mice (Sansom et al, 2005). Expression analysis of MBD
proteins in tumours has revealed increased overall levels
associated with enhanced proliferation (Esteller, 2005a). Mutations
in MBDs do occur in sporadic tumours, albeit rarely (Bader et al,
2003). MBD4 is an exception and is frequently targeted by
inactivating frameshift mutations in microsatellite-unstable
tumours (Riccio et al, 1999). However, we should keep in mind
that MBD4 is unusual: it has a glycosylase domain that removes
thymidine from T:G mismatches.
GENES MEDIATING THE DISRUPTION OF HISTONE
MODIFICATIONS
A first draft of an aberrant histone modification signature for
human cancer has been produced (Fraga et al, 2005; Fraga and
Esteller, 2005; Seligson et al, 2005). The next task is to identify the
molecules involved in its establishment: histone acetyltransferases
(HATs), histone methyltransferases (HMTs) and histone deacety-
lases (HDACs).
With respect to histone acetylation, we have found a loss of
recruitment of a family of the specific K-16 HATs MOZ, MOF and
MORF to DNA-repetitive sequences in cancer cells (Fraga et al,
2005). These HATs are already altered in leukaemias by the
generation of fusion proteins such as MOZ-CBP and MORF-CBP
that are also associated with significant global losses of acetylation
of K16-H4 (Fraga et al, 2005). What makes the case even more
interesting is that the other partner of the fusion protein generated
is usually CBP or p300, two other HATs with numerous substrates,
but that do not act on lysine 16 of H4 (Fraga and Esteller, 2005). A
tumour-suppressor role for these global HATs has been strongly
suggested from many sources: CBP, p300 and pCAF somatic
mutations have been described in primary human tumours
(Gayther et al, 2000; Ozdag et al, 2002; Ionov et al, 2004;
Kishimoto et al, 2005); patients with Rubinstein–Taybi syndrome,
caused by germline mutations in the CBP gene, have an increased
tendency to develop tumours at an early age (Gibbons, 2005);
and CBP heterozygous mice develop haematological tumours
(Gibbons, 2005).
In the case of HDAC, the deacetylation of K16-H4 seems to be
particularly closely regulated: in yeast, Sir2 deacetylates this
residue, and its human homologue, Sirtuin 1 (SIRT1), also
deacetylates the tumour-suppressor protein p53, thereby establish-
ing another link with cancer. We can view the picture from this
angle and hypothesise that there is increased recruitment of SIRT1
to the K16-H4 position in repeat DNA sequences in the
transformed cell. In this regard, overexpression of SIRT1 is
observed in leukemia cells (Bradbury et al, 2005). For HDACs with
a broader deacetylation specificity than SIRT1, such as HDAC1
and HDAC2, no somatic mutations in tumours have been
described, but a dysregulated expression seems to be a common
feature of human neoplasia (Gibbons, 2005).
A similar scenario could be proposed for the trimethylation of
lysine 20 of H4 (Fraga et al, 2005). This reaction is catalysed by the
HMTs Suv4-20h1 and Suv4-20h2, in addition to PR/SET7-SET8
(Fraga and Esteller, 2005). These enzymes can be targets for
disruption in cancer cells, as occurs with another HMT, MLL1,
which is translocated to multiple partners in haematological
malignancies (Fraga and Esteller, 2005). The loss of trimethylation
of histone H4 in cancer cells might be a consequence of a
deficiency of these enzymatic activities in tumours, and/or a lack
of recruitment to heterochromatic regions, where most of the
histones containing such modifications are localised. We should
keep in mind that mice deficient in SUV39H1 HMTs (which target
lysine 9 of histone H3) have increased chromosomal instability and
tumour risk (Peters et al, 2001) and another K9-H3 histone
methyltransferase, RIZ1, undergoes CpG island hypermethylation-
associated silencing in many tumour types (Esteller, 2005a). Lack
of HMTs specific to K20-H4 has not yet been described in
tumours, but all these issues can now be addressed with new tools,
such as specific antibodies against Suv4-20h (Fraga et al, 2005).
GENES MEDIATING THE DISRUPTION OF
CHROMATIN REMODELLING
Polycomb-group (PcG) and trithorax-group (trxG) genes are
epigenetic silencers and activators for gene transcription, respec-
tively (Valk-Lingbeek et al, 2004; Raaphorst, 2005). Both are part
of multitask protein complexes including HDAC and HMTs
activities. In the case of the human homologue of trithorax,
MLL, I have already mentioned the existence of translocations that
generate transforming fusion proteins (Gibbons, 2005). For PcG in
human there are two complexes, polycomb repressive complex 1
(PRC1) and 2 (PRC2), which contain the BMI1 and enhancer of
zeste homologue 2 (EZH2) oncogenes, respectively (Valk-Lingbeek
et al, 2004; Raaphorst, 2005). BMI1 downregulates the expression
of tumour-suppressor genes, such as p16
INK4a and p14
ARF
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predisposition to lymphomagenesis, subtypes of human lympho-
mas harbour BMI1 gene amplification and overexpression and it
induces cell immortalisation (Valk-Lingbeek et al, 2004; Raa-
phorst, 2005). EZH2 undergoes gene amplification in several
tumour types (Bracken et al, 2003), it is overexpressed in prostate
and breast cancers, and its downregulation leads to growth
inhibition (Raaphorst, 2005).
Another powerful epigenetic repressor family of chromatin-
remodelling factors is the Tudor domain ‘Royal Family’ (Hughes-
Davies et al, 2003). Two of its members, HP1 and BS69, bind to
EMSY. The latter gene is a critical component in breast cancer
development in the BRCA2 pathway. Most importantly, EMSY
behaves as an oncogene in mammary neoplasm, where it shows
gene amplification (Hughes-Davies et al, 2003). The list of targeted
epigenetic repressors also includes Breast Cancer Metastasis
Suppressor 1 (BRMS1), which is able to inhibit metastasis without
‘touching’ tumorigenesis itself (Meehan and Welch, 2003). BRMS1
joins the mSin3a HDAC complexes to silence the targeted genes
(Meehan and Welch, 2003). An opposing force to BRMS1 is
the group of metastasis-associated genes (MTAs). MTA1, MTA2,
and MTA3 are components of the nucleosome remodelling
and deacetylation complex, as a part of the NuRD complex.
Metastasis-associated gene 1 overexpression is associated with the
most malignant behaviour in several human tumours. Metastasis-
associated gene 3 has a predominant role in lymphoma and breast
cancer, in the latter leading to aberrant expression of the
transcriptional repressor Snail and loss of expression of the cell-
adhesion molecule E-cadherin, an event associated with invasive
growth of breast cancers (Fujita et al, 2003).
The best-recognised chromatin remodelling ‘force’ is the SWI/
SNF family of ATP-hydrolysing enzymes (Gibbons, 2005). These
are multiprotein complexes, as we have seen in the case of the PcG,
but in this case with transcriptional activation properties. Among
the many members of the SWI/SNF family, four are involved with
cancer development: PASG/LSH, BRG1, HLTF and SNF5. Potential
mutations of PASG/LSH have been identified in leukaemia (Lee
et al, 2000); BRG1 genetic alterations occur in several tumour types
and the reintroduction of the gene inhibits cell growth (Medina
et al, 2005); helicase-like transcription factor (HLTF) undergoes
methylation-associated silencing in different neoplasms (Esteller,
2005a); and SNF5 shows inactivating somatic and germline
mutations in malignant rhabdoid tumours (Imbalzano and Jones,
2005).
TARGETING EPIGENETIC GENES IN CANCER
THERAPY
The ‘holy grail’ of current research in cancer therapy is the design
of specific drugs against molecular alterations found only in the
transformed cell, such as mutations in oncogenes. Epigenetics can
offer many new targets for this approach. However, only two types
of epigenetic drugs, neither of which is very specific, have
nowadays a real impact: DNA-demethylating agents and histone
deacetylase inhibitors (HADCis) (Villar-Garea and Esteller, 2004;
Esteller, 2005b). We have to be patient with other potential
epigenetic drugs, such as histone acetyltransferase inhibitors,
including anacardic acid, curcumin, and peptide CoA conjugates;
in addition to undisclosed histone methyltransferase inhibitors or
those HDACis that are specific for SIRT1 (class III HDAC), such as
nicotinamide and splitomycin.
Of the class of DNA-demethylating agents, the first drug used to
inhibit DNA methylation was 5-azacytidine (Vidaza). This
substance causes covalent arrest of DNMTs, resulting in cytotoxi-
city. 5-Azacytidine was tested for its usefulness as an antileukaemic
drug before its demethylating activity was known (Esteller, 2005b).
The analogue 5-aza-20-deoxycytidine (Decitabine) is one of the
most commonly used demethylating drugs in assays with cultured
cells. Zebularine is another recently developed cytidine analogue
(Yoo et al, 2004). It forms a covalent complex with DNA
methyltransferases (Yoo et al, 2004). Furthermore, zebularine
has also shown promising antitumoral effects in xenografts (Yoo
et al, 2004) and thymic lymphomas (Herranz et al, 2005) in mice.
Perhaps the most interesting feature of this DNA-demethylating
agent is that it is chemically stable and of low toxicity (Yoo et al,
2004; Herranz et al, 2005), and can be taken orally. It is in the field
of haematological malignancies that DNA-demethylating agents
have had their greatest success so far, especially in high-risk
myelodysplastic syndrome using 5-aza-2-deoxycytidine (Esteller,
2005b). In 2004, the FDA approved the use of 5-azacytidine
(Vidaza) for the treatment of all myelodysplastic syndrome
subtypes.
On the other hand, naturally occurring and synthetic HDACis
are also the focus of interest because of their great potential utility
against cancer. Overall, HDACis manifest a wide range of activities
against all HDACs. These compounds can be classified into the
following groups according to their chemical nature: hydroxamic
acids, such as trichostatin A, SAHA, PXD101 and NVP-LAQ-824;
carboxylic acids, such as sodium valproate and butyrate;
benzamides, such as MS-272 and others, including trapoxins and
FK228 (Villar-Garea and Esteller, 2004). It is believed that the
anticancer effects of HDACis are mediated by the reactivation of
the expression of tumour-suppressor genes. However, the treat-
ment of cancer cell lines with HDACis has pleiotropic effects
inducing differentiation, cell-cycle arrest and apoptosis. In this
regard, the observation that cancer cells have lost monoacetylated
lysine 16 histone H4 (Fraga et al, 2005) implies a new molecular
pathway that may explain the beneficial effects of HDAC inhibitors
because these compounds may promote the restoration of normal
histone H4 acetylation levels in the whole cell, restoring the normal
chromatin status of repetitive DNA sequences (Fraga et al, 2005). It
is clear from in vitro, preclinical studies and ongoing clinical trials
that HDACis have enormous potential as anticancer drugs. In this
regard, SAHA may soon be approved for the treatment of
cutaneous lymphoma.
CONCLUSIONS
Cancer is a genetic and epigenetic disease. We cannot study and
explore one field and ignore the other. The overall disruption of
the epigenetic landscape is the most common feature of all human
tumours. This includes global loss of genomic DNA methylation,
local CpG island hypermethylation-associated gene silencing and a
characteristic histone modification pattern. Stochastic and selec-
tive forces drive the whole process, and in the same way as in the
cell cycle, apoptosis and DNA repair genes are targeted, genes
involved in DNA methylation, histone modification and chromatin
remodelling also become disrupted. Some of these will act as
oncogenes, others as tumour-suppressor genes. Some will be
altered by genetic lesions, others by epigenetic lesions. Ultimately,
we will have to find better drugs to combat both processes.
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